FoxKiser

The story of FoxKiser begins with its founding partners, Allan Fox and John Daniel Kiser. They established a firm designed to operate at the intersection of science, law, and medicine. The company's focus was on providing strategic advice and counsel to companies in the pharmaceutical and biotechnology sectors. FoxKiser built its business by identifying opportunities and improving the market position for its clients within highly regulated industries, particularly healthcare. A key part of their strategy involved creating and building new ventures. A notable example is their involvement with REGENXBIO, a company specializing in gene therapy. FoxKiser Holdings, a limited liability company, was established to hold assets for the founders, and it played a role in REGENXBIO's journey. This culminated in a significant event in September 2015, when shares held by FoxKiser converted to common stock during REGENXBIO's Initial Public Offering. This move illustrates the firm's model of fostering and capitalizing on growth in the biomedical field.